Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes

Publication date: March 2016
Source:European Journal of Cancer, Volume 56
Author(s): Liza C. Villaruz, Mark A. Socinski
Nab-paclitaxel is a novel therapeutic agent, which was approved in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC) regardless of histologic subtype in the United States of America by the Food and Drug Administration in 2012 and by the European Commission in 2015. This approval was based on the results of a phase III clinical trial showing superior response rates compared with solvent-based paclitaxel in combination with carboplatin. This review will focus on the early development and clinical data to date supporting the use of nab-paclitaxel in advanced NSCLC. The clinical question central to this review is whether nab-paclitaxel has a place in the current therapeutic landscape of advanced NSCLC.



from Cancer via ola Kala on Inoreader http://ift.tt/1XoFi9o
via IFTTT